Myteka Tablet 10mg (Montelukast)
Hilton Pharma (Pvt) LtdDRAP reg. 030051
We dispense this on prescription
We accept a prescription from any registered doctor in Pakistan.
Same day or next day in Karachi, Lahore, Islamabad, Rawalpindi for orders confirmed before 6pm. Tracked courier, 2 to 4 working days everywhere else. Delivery Rs 250 in Rawalpindi and Islamabad, Rs 300 everywhere else, cash on delivery. Delivery details
Prices in PKR, checked 23 October 2026.
What Myteka is
Myteka (montelukast) is used to prevent and control asthma, to prevent exercise-induced narrowing of the airways, and to relieve allergic rhinitis when other treatments haven’t worked or can’t be taken, according to the US label for Singulair (Organon). We dispense it on prescription.
- It can cause serious mental health side effects: DRAP’s Safety Alert No. 11 says to stop taking montelukast and tell a health care professional right away if you or your child have behaviour or mood changes. See the warning below.
- It does not treat an asthma attack that has already started: keep your usual reliever inhaler for that.
- Registered with DRAP under number 030051. (DRAP registry entry) for the 10 mg tablet.
- Made by Hilton Pharma, Karachi, according to DRAP’s alerts naming the product. We found no Hilton leaflet online, so no Pakistani document we could find states its uses or condition of sale; dispensing it on prescription is our own policy.
- Falsified Myteka 10 mg has been found in Pakistan, and two batches of Myteka sachets were recalled as substandard. See the genuine-pack checks below.
- DRAP notifies no price for Myteka: every pack is de-controlled, and the price index has no entry.
What is in each tablet and sachet
One active ingredient, montelukast, from the label claims in DRAP’s registry.
| Form | Ingredient | DRAP label claim |
|---|---|---|
| Myteka 10mg tablet (DRAP reg. 030051) | Ingredient: Montelukast 10 mg (as montelukast sodium) | DRAP label claim: “Each film coated tablets contains: Montelukast Sodium, USP equivalent to Montelukast Acid …… 10 mg” |
| Myteka 5mg chewable tablet (DRAP reg. 030050) | Ingredient: Montelukast 5 mg (as montelukast sodium) | DRAP label claim: “Each tablet contains:- Montelukast Sodium eq. to Montelukast Acid …… 5 mg” |
| Myteka 4mg chewable tablet (DRAP reg. 034658) | Ingredient: Montelukast 4 mg (as montelukast sodium) | DRAP label claim: “Each chewable tablet contains: Montelukast Sodium, USP equivalent to Montelukast Acid…......4mg” |
| Myteka 4mg sachet (DRAP reg. 039695) | Ingredient: Montelukast 4 mg (as montelukast sodium) | DRAP label claim: “Each sachet contains: Montelukast Sodium, USP equivalent to Montelukast...................4mg” |
What it is used for
Asthma and allergy. The US and UK labels set different limits on when it should be used.
| Label | Uses |
|---|---|
| US, Singulair (Organon) | Prevention and long-term treatment of asthma from 12 months of age; prevention of exercise-induced bronchoconstriction from 6 years; relief of seasonal allergic rhinitis from 2 years and year-round allergic rhinitis from 6 months, reserved for people with an inadequate response to, or who cannot tolerate, other treatments. |
| UK, Singulair 10 mg (Organon) | Add-on treatment for mild to moderate persistent asthma not controlled on an inhaled steroid and a reliever; in those patients it can also relieve seasonal allergic rhinitis. Also prevention of asthma that is mainly exercise-induced. |
| Pakistan, DRAP Safety Alert No. 11 | Advises prescribing montelukast for allergic rhinitis only to patients who have an inadequate response to, or cannot tolerate, other treatments. |
Neither label lists cough as a use. The UK children’s chewable labels give asthma uses only, not allergic rhinitis.
Warning: mental health and behaviour changes
The US label for Singulair (Organon) carries a boxed warning: serious neuropsychiatric events, including agitation, aggression, depression, sleep disturbances and suicidal thoughts and behaviour (including suicide), have been reported.
- Stop and get advice: DRAP’s Safety Alert No. 11 tells patients to stop taking montelukast and notify a health care professional right away if they or their child experience behaviour or mood-related changes.
- Changes to watch for, from the FDA’s 2020 safety communication: agitation, aggression or hostility; attention or memory problems; bad or vivid dreams; depression; confusion; anxiety; hallucinations; irritability; obsessive-compulsive symptoms; restlessness; sleepwalking; stuttering; suicidal thoughts and actions; tremor; trouble sleeping; uncontrolled muscle movements.
- Before starting, DRAP’s alert advises talking to your health care professional about any history of mental illness.
- Symptoms may outlast treatment: the UK product information for Aurobindo’s montelukast granules says some neuropsychiatric symptoms may persist after montelukast is stopped.
- Tell family and friends: the UK regulator, MHRA, says it is very important to tell your friends and family that you are taking montelukast.
How to take it
Once a day in the evening, according to the UK product information for Singulair 10 mg tablets (Organon); your doctor decides the form and strength.
- Ages: the UK labels say do not give the 10 mg tablets to children under 15, the 5 mg chewable tablets to children under 6 or the 4 mg chewable tablets to children under 2. The UK granules label says granules are not recommended below 6 months of age.
- Chewable tablets are chewed before swallowing. The UK 5 mg chewable label says that if taken in connection with food, take it 1 hour before or 2 hours after food.
- Sachets: follow the instructions on the Myteka pack. For comparison, the UK label for montelukast 4 mg granules says to give the full dose within 15 minutes of opening, mixed with a spoonful of cold or room-temperature soft food.
- Keep taking your asthma steroid: the UK label says montelukast should not be substituted abruptly for inhaled or oral corticosteroids.
Who should not take it, or should ask a doctor first
From the UK product information for Singulair 10 mg tablets (Organon) unless another label is named.
- Must not take it: anyone allergic to montelukast or any ingredient.
- Anyone with a history of mental illness: tell the doctor first (DRAP Safety Alert No. 11).
- Aspirin-sensitive asthma: montelukast does not change the need to avoid aspirin and other non-steroidal anti-inflammatory painkillers.
- Phenylketonuria (PKU): the UK Singulair chewable tablets contain aspartame, a source of phenylalanine. We haven’t seen Myteka’s ingredient list, so ask our pharmacist before ordering a chewable tablet.
- Very young children: the UK granules label says a diagnosis of persistent asthma in children aged 6 months to 2 years should be made by a paediatrician or lung specialist.
Other medicines
Many medicines, including common asthma medicines, need no dose change with montelukast; a few lower or raise its level.
| Medicine | What happens | Source |
|---|---|---|
| Phenytoin and phenobarbital (for epilepsy), rifampicin (for tuberculosis) | What happens: They can lower montelukast levels: the label advises caution, particularly in children. | Source: UK, 4.5 |
| Gemfibrozil (for cholesterol) | What happens: It raised exposure to montelukast 4.4-fold in a study. | Source: UK, 4.5 |
| Theophylline, prednisone, prednisolone, oral contraceptives, fexofenadine, digoxin, warfarin, thyroid hormones, painkillers such as NSAIDs | What happens: No dose change is needed. | Source: US, section 7 |
Pregnancy and breastfeeding
The UK label allows it in pregnancy and breastfeeding only if clearly essential; the US label reports no established risk.
| Who | What the labels say |
|---|---|
| Pregnancy | UK: may be used only if considered clearly essential. US: decades of published studies in pregnant women have not established a drug-associated risk of major birth defects. |
| Breastfeeding | UK: it is unknown whether it passes into milk; may be used only if clearly essential. US: a study found montelukast in human milk, and the data do not suggest a significant risk of side effects for the baby. |
Side effects
From the UK product information for Singulair 10 mg tablets (Organon), by how often they occur.
| How often | Side effects |
|---|---|
| Very common | Upper respiratory infection. |
| Common | Diarrhoea, nausea, vomiting; rash; fever; raised liver enzymes in blood tests. |
| Uncommon | Abnormal dreams including nightmares, sleeplessness, sleepwalking, anxiety, agitation including aggression, depression, restlessness and irritability; dizziness, drowsiness, fits; allergic reactions including anaphylaxis; nosebleed; joint and muscle pain; bed-wetting in children; tiredness, swelling. |
| Rare | Attention and memory problems, tic, tremor; palpitations; bleeding more easily; swelling under the skin (angioedema). |
| Very rare | Hallucinations, disorientation, suicidal thoughts and behaviour, obsessive-compulsive symptoms, stuttering; hepatitis; Churg-Strauss syndrome. |
Driving: the UK label says it has no or negligible effect on driving, but some people have reported drowsiness or dizziness.
Checking your pack is genuine
We found three DRAP alerts naming Myteka: one about a falsified 10 mg tablet and two recalling substandard sachets.
- Buy only from a licensed pharmacy: DRAP’s falsified-Myteka alert says all therapeutic goods must be obtained from licensed pharmacies and other authorised outlets, and that the authenticity and condition of products should be carefully checked.
- Check the batch number on the carton and blister against the batches below, and that the pack is sealed. DRAP’s falsified-tablet alert names only the batch number, with no other features to tell the fake apart.
- If you have a pack from a listed batch, stop using it: DRAP asks consumers to stop and to contact their doctor if they had any problem after taking it.
DRAP Alert No. I/S/10-25-91 (falsified), 16 October 2025: Myteka 10 mg tablets, batch 156428, declared spurious by the Drug Testing Laboratory, Punjab: testing found no active ingredient, and Hilton Pharma has formally disowned the product.
DRAP Alert No. I/S/10-25-105 (substandard), 30 October 2025: Myteka Sachet 4 mg (DRAP reg. 039427), batch 155321, declared substandard on the impurities test. Unlike the falsified tablet above, the alert names Hilton Pharma as the maker, not as a purported one.
DRAP Alert No. I/S/4-25-37 (substandard), 22 April 2025, posted 25 April 2025: Myteka Sachet 4 mg (DRAP reg. 039695), batch 155384, made by Hilton Pharma, reported substandard on the assay test and the test for organic impurities.
We buy only from authorised distributors, and check the batch and expiry on every item before it is packed.
Information as of 22 October 2026. DRAP publishes new alerts on dra.gov.pk.
Returns and replacements
Medicines and supplements can’t be returned once they have left our pharmacy.
- Returned medicine can never go back into saleable stock. That is a safety rule, not a commercial one.
- If an item arrives damaged or wrong, tell us on WhatsApp within 24 hours and we replace it. That is us fixing our mistake, not a return.
- Anything that arrives expired or within a month of expiry we replace or refund, your choice, with no time limit.
Frequently asked questions
What is Myteka tablet used for?
Myteka contains montelukast. The US label lists the prevention and long-term treatment of asthma, prevention of exercise-induced narrowing of the airways, and relief of allergic rhinitis, but reserves allergic rhinitis for people for whom other treatments haven’t worked or can’t be taken. DRAP’s Safety Alert No. 11 gives the same advice for allergic rhinitis.
Is Myteka used for cough?
No label we read lists cough as a use. The US label lists cough among the most common side effects in trials. For a cough that lasts, see a doctor.
Can this medication be used for asthma attacks?
No. The US label says it is not indicated for an acute asthma attack, and the UK label says never to use it to treat one: keep your usual reliever inhaler for attacks.
Why Montelukast is taken at night?
The UK labels say to take it once daily in the evening, and the US label says people with both asthma and allergic rhinitis should take one dose daily in the evening. The labels we read don’t give a reason.
Does Myteka 10 mg tablet affect contraception?
The US label says no dose adjustment is needed when montelukast is taken with oral contraceptives.
What is Myteka sachet used for?
Myteka sachets contain 4 mg of montelukast (DRAP reg. 039695). DRAP’s registry does not say what age group they are for, so ask your doctor or our pharmacist. For comparison, the UK label for montelukast 4 mg granules covers asthma in children from 6 months to 5 years and says the granules are not recommended below 6 months. The same mental health warning applies to children: watch for behaviour or mood changes.
Questions about Myteka Tablet 10mg (Montelukast)?
Send your question on WhatsApp and a pharmacist will come back to you.
Written by the ePharmacyy pharmacy team.
Last checked against the sources below on
DRAP registration
- Myteka 10mg Tablets (030051), Hilton Pharma (Pvt) Ltd. DRAP’s registry shows: Reviewed, “Not Verified”.
- Myteka 5mg Tablets (030050), Hilton Pharma (Pvt) Ltd. DRAP’s registry shows: Provisionally Active, “Not Verified”.
- Myteka 4mg Chewable Tablet (034658), Hilton Pharma (Pvt) Ltd. DRAP’s registry shows: Provisionally Active, “Not Verified”.
- Myteka 4mg Sachet (039695), Hilton Pharma (Pvt) Ltd. DRAP’s registry shows: Provisionally Active, “Not Verified”.
- Myteka Sachet (039427), Hilton Pharma (Pvt) Ltd. DRAP’s registry shows: Provisionally Active, “Not Verified”.
DRAP publishes no definition of this verification flag, so we can’t tell you what it means. We searched DRAP’s website for “Myteka” and “montelukast” on 22 October 2026 and found three alerts naming Myteka, one falsified and two substandard, listed under the genuine-pack checks below, and alerts on other companies’ montelukast products. When we tested it, the search did not find a word that appears only inside an alert’s attached PDF, so an alert that names a product only in its PDF may not show up. DRAP describes its registered products index as a provisional list that “cannot be used as a reference for any purpose”. Checked against the registry on .
Sources
- DRAP registered products: Myteka 10mg Tablets, registration 030051
- DRAP registered products: Myteka 5mg Tablets, registration 030050
- DRAP registered products: Myteka 4mg Chewable Tablet, registration 034658
- DRAP registered products: Myteka 4mg Sachet, registration 039695
- DRAP notified price index (no entry for Myteka or montelukast)
- DRAP Safety Alert No. 11: serious mental health side effects with montelukast, 6 April 2020 (PDF)
- DRAP Alert No. I/S/10-25-91: falsified Myteka 10 mg, batch 156428, 16 October 2025 (PDF)
- DRAP Alert No. I/S/10-25-105: substandard products including Myteka Sachet batch 155321, 30 October 2025 (PDF)
- DRAP Alert No. I/S/4-25-37: substandard products including Myteka Sachet batch 155384, 22 April 2025 (PDF)
- DailyMed (US): Singulair tablets, chewable tablets and oral granules, Organon LLC, prescribing information
- US FDA Drug Safety Communication: boxed warning about serious mental health side effects for montelukast, 4 March 2020
- emc (UK): Singulair 10 mg film-coated tablets, Organon, summary of product characteristics (revised 31 August 2026)
- emc (UK): Singulair Paediatric 5 mg chewable tablets, Organon, summary of product characteristics (revised 31 August 2026)
- emc (UK): Singulair Paediatric 4 mg chewable tablets, Organon, summary of product characteristics (revised 31 August 2026)
- emc (UK): Montelukast 4 mg oral granules, Sandoz, summary of product characteristics (revised 7 May 2024)
- emc (UK): Montelukast 4 mg granules, Aurobindo/Milpharm, summary of product characteristics (revised 15 July 2026)
- MHRA Drug Safety Update: montelukast, reminder of the risk of neuropsychiatric reactions, 29 April 2024
- MHRA Drug Safety Update: montelukast (Singulair), reminder of the risk of neuropsychiatric reactions, 19 September 2019